A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-525016-41-00

Enrollment

Registered

2026-08-04

Start date

Unknown

Completion date

Unknown

Last updated

2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Brief summary

Change from baseline in FVC (mL)

Detailed description

1. Change from baseline in FVC (mL), 2. Change from baseline in % predicted FVC, 3. Slope (rate of decline) in FVC (mL/week), 4. AEs, DAEs, SAEs, AESIs, vital signs, clinical laboratory assessments (eg, clinical chemistry, hematology, urinalysis), ECGs, 5. AZD8965 plasma concentrations

Interventions

DRUGAZD8965

DRUGPlacebo to AZD8965

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in FVC (mL)	—

Secondary

Measure	Time frame
1. Change from baseline in FVC (mL), 2. Change from baseline in % predicted FVC, 3. Slope (rate of decline) in FVC (mL/week), 4. AEs, DAEs, SAEs, AESIs, vital signs, clinical laboratory assessments (eg, clinical chemistry, hematology, urinalysis), ECGs, 5. AZD8965 plasma concentrations	—

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 5, 2026